Lahore: Liven Pharma Limited has approved a significant expansion of its authorized share capital, as confirmed during an Extraordinary General Meeting held on August 18, 2025. The authorized capital of the company will rise from PKR 1.00 billion to PKR 1.20 billion, a move aimed at facilitating future share issuance.

The decision, which was first recommended by the Board of Directors on July 22, 2025, involves increasing the number of ordinary shares from 100 million to 120 million, each with a face value of PKR 10. According to information available from the Pakistan Stock Exchange (PSX), this adjustment will not alter the rights and privileges associated with the current shares, as the new shares will be on equal footing with the existing ones.

Additionally, the enhancement of the authorized share capital has prompted necessary amendments to Clause V of the company's Memorandum of Association. These amendments are designed to accurately reflect the increased authorized share capital.

This development categorizes as a Very large or significant move within the designated market category, indicating a robust strategic positioning for the company in anticipation of its future financial and operational growth.